AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...